Medical Condition News

RSS

Alternative therapy for hypertension

New research from the Northwestern University Feinberg School of Medicine has found that an alternative therapy may be possible for treating some types of hypertension using an enzyme called ACE2.

18 Dec 2009

Hydrocephalus Association awards stimulus grants for research initiative

The Hydrocephalus Association has announced research grants to scientists at five medical centers, in a new initiative to address the shortfall in progress in the treatment of hydrocephalus, a condition affecting one million Americans.

17 Dec 2009

PRPS1 gene associated with DFN2 identified by researchers

A gene associated with a rare form of progressive deafness in males has been identified by an international team of researchers funded by the National Institute on Deafness and Other Communication Disorders.

17 Dec 2009

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.

17 Dec 2009

Switching between A-rated anti-epileptic drug formulations does not increase seizure risk

Express Scripts, Inc., one of the largest pharmacy benefit management companies in North America, announced today results of a study that examined the association of seizure risk among epilepsy patients after switching between A-rated anti-epileptic drug formulations. The study found no evidence that switching between A-rated anti-epileptic drugs, including brand to generic substitution, was associated with increased emergency room visits or hospitalizations for epilepsy.

17 Dec 2009

Interleukin Genetics introduces the Bone Health Genetic Test

Interleukin Genetics, Inc. announced today availability of the Bone Health Genetic Test designed to detect genetic patterns associated with the development of osteoporosis-related outcomes. The test determines an individual's risk for developing vertebral or spinal fractures and low bone mineral density.

17 Dec 2009

RevMed MRI Technology converts standard grayscale scans to segmented, 3D, color images

Revolutions Medical Corporation, producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced today that recent mass media reports that CT scans cause cancer could rapidly elevate MRI as the technology of choice for musculoskeletal scans and more.

17 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint was achieved in the Company’s Phase 2 pain study assessing the efficacy and safety of BEMA Buprenorphine. The positive results follow BDSI’s March 2009 announcement of favorable Phase 1 study results.

17 Dec 2009

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

It should be possible to use therapeutic vaccines to create both cheap and effective drugs for diseases like cancer and allergies. One problem in developing such vaccines has previously been the lack of adjuvants, substances that make vaccines more effective. However, there has now been a major breakthrough in this area. The study, led by Swedish scientists at Uppsala University, is published in the December issue of the journal Vaccine.

17 Dec 2009

Investigational study of TRT to alleviate debilitating effects of tinnitus commenced

A University of Alabama researcher is embarking on a $5.6 million phase-three, randomized, controlled clinical trial to evaluate the effectiveness of an innovative treatment that uses a noise-generating device, along with counseling, to alleviate the debilitating effects of tinnitus - that ringing in the ears that drives some people to distraction.

17 Dec 2009

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Applied Biosystems, part of Life Technologies Corporation, today announced the publication of a paper in the journal Nature that demonstrates the power of next-generation DNA sequencing used to identify DNA mutations in a small cell lung cancer (SCLC) line and identify the mutational burden associated with tobacco smoking.

17 Dec 2009

Sporting Turn the Tables to return for the second time

CANCER Research UK's Sporting Turn the Tables will return for the second time on Monday 18 January 2010, with legends from the world of sport putting some of the nation's favourite sports journalists in the hot seat.

17 Dec 2009

ASA offers practical ways for sufferers to take active role in treatment of pain

Whether the result of injury, illness or a chronic condition, 70 million Americans experience pain annually. The individual pain sufferer may experience a diminished quality of life, lack of mobility and added stress.

17 Dec 2009

Typical smoker acquires one mutation for every 15 cigarettes and all cancers are caused by mutations

Research teams led by the Wellcome Trust Sanger Institute announce the first comprehensive analyses of cancer genomes.

17 Dec 2009

ESC CV Imaging textbook for trainees and cardiologists

Imaging is at the heart of diagnostic procedures in cardiology. The idea of publishing an ESC Textbook of Cardiovascular Imaging which accumulates the expertise of European cardiovascular imagers, is therefore long awaited.

17 Dec 2009

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.

17 Dec 2009

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

Scientists at deCODE genetics, Inc. publish in the journal Nature the discovery of a version of a common single-letter variant in the sequence of the human genome (SNP) with a major impact on susceptibility to type 2 diabetes (T2D).

17 Dec 2009

Professional treatment can benefit first responders to cope with emotional challenges

Professional first responders are prepared, equipped and trained to handle various emergency situations, from car accidents to terrorist attacks and other major disasters. Today, however, this great responsibility can be particularly burdensome on one's emotions.

17 Dec 2009

RRE-90 score: A new web-based tool to predict recurrent stroke risk

Scientists have developed a new web-based tool that may better predict whether a person will suffer a second stroke within 90 days of a first stroke, according to research published in the December 16, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.

17 Dec 2009

Medical Condition News

Alternative therapy for hypertension

Hydrocephalus Association awards stimulus grants for research initiative

PRPS1 gene associated with DFN2 identified by researchers

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Switching between A-rated anti-epileptic drug formulations does not increase seizure risk

Interleukin Genetics introduces the Bone Health Genetic Test

RevMed MRI Technology converts standard grayscale scans to segmented, 3D, color images

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

Promising breakthrough in adjuvant development may lead to cost-effective therapeutic vaccines

Investigational study of TRT to alleviate debilitating effects of tinnitus commenced

Next-generation DNA sequencing demonstrates potential in identifying mutations in SCLC

Sporting Turn the Tables to return for the second time

ASA offers practical ways for sufferers to take active role in treatment of pain

Typical smoker acquires one mutation for every 15 cigarettes and all cancers are caused by mutations

ESC CV Imaging textbook for trainees and cardiologists

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Discovery of common single-letter variant in SNP links parental origin to risk of T2D

Professional treatment can benefit first responders to cope with emotional challenges

RRE-90 score: A new web-based tool to predict recurrent stroke risk

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News